# Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

> **NCT07342803** · PHASE2 · RECRUITING · sponsor: **Longbio Pharma** · enrollment: 200 (estimated)

## Conditions studied

- Allergic Asthma

## Interventions

- **BIOLOGICAL:** LP-003 Injection
- **BIOLOGICAL:** Omalizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07342803
- **Lead sponsor:** Longbio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-25
- **Primary completion:** 2027-12-28
- **Final completion:** 2029-09-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342803, "Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07342803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*